Firms
Theme

ABM

ABM Industries, Inc. · NYSE

News

7 latest

Zacks Investment Research

Here's Why You Should Hold ABM Stock in Your Portfolio Now

ABM Industries stock has outperformed the market with a 28.2% gain over six months, driven by strong growth in high-margin infrastructure markets including semiconductors, microgrids, and data centers. The company raised FY26 free cash flow guidance to $210M and achieved its below-3X leverage target ahead of schedule. However, macroeconomic headwinds in commercial real estate and airline sectors, combined with rising debt and interest expenses, pose risks to future growth.

Zacks Investment Research

Zacks Industry Outlook Highlights Concentrix, Sodexo and ABM Industries

Zacks analyzes three business services stocks amid industry challenges. Concentrix is transitioning to AI-enabled customer experience solutions with improving margins.

Zacks Investment Research

3 Business Services Stocks to Consider Amid Industry Woes

The Business Services industry is underperforming the S&P 500, trading at a lower valuation multiple (13.58X vs 19.87X P/E). Three key companies—Concentrix, Sodexo, and ABM Industries—are benefiting from AI integration, outsourcing demand, and infrastructure investment, though they face headwinds from labor shortages and wage inflation. Concentrix leads in AI-enabled customer experience solutions with improving margins, Sodexo shows resilient organic growth in food and facilities management, and ABM is expanding in high-growth semiconductor and data center markets.

Zacks Investment Research

ABM Industries (ABM) Down 2% Since Last Earnings Report: Can It Rebound?

ABM Industries beat Q3 fiscal 2026 earnings expectations with adjusted EPS of $1.04 (up 27% YoY) and revenues of $2.32 billion (up 4.2% YoY). The company raised its full-year guidance and showed strong growth in high-margin semiconductor, microgrid, and data center segments. However, shares have underperformed the S&P 500 by 2% since the earnings report, with the stock rated a Hold (Zacks Rank #3).

Mentions ABM

Zacks Investment Research

Strength Seen in AMN Healthcare (AMN): Can Its 8.9% Jump Turn into More Strength?

AMN Healthcare shares surged 8.9% to $46.82, driven by investor optimism about recovery in healthcare staffing demand and stronger-than-expected Q2 2026 results. However, the stock carries a Zacks Rank #3 (Hold) rating as earnings estimate revisions have remained flat over the past 30 days, suggesting the recent momentum may not sustain without positive estimate changes.

Zacks Investment Research

Equifax Q3 Earnings Beat Estimates, Revenues Increase Y/Y

Equifax reported Q3 adjusted EPS of $2.26 (up 10.8% YoY) and revenues of $1.69 billion (up 9.6% YoY), beating consensus estimates. However, the company cut its 2026 revenue guidance midpoint to $6.661 billion due to weaker U.S. mortgage demand, offsetting strong growth in USIS (up 13%), Workforce Solutions (up 7%), and international operations (up 9%).

Zacks Investment Research

ACN Set to Report Q4 Earnings: Here's What Investors Should Know

Accenture is expected to report Q4 fiscal 2026 results on October 1 with revenues estimated at $18B (up 5.6% YoY) and EPS projected at $3.19 (up 5.3% YoY). Growth is anticipated across most segments driven by AI demand and consulting capabilities, though Asia Pacific revenues are expected to decline 26.4%. The company has a positive earnings surprise history and an Earnings ESP of +0.31%.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $ABM · 0 threads

Sign in to post on $ABM

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev